Cells are very important to researchers due to their use in various biological studies in in vitro and in vivo settings. This importance stems from the short lifespan of most cells under laboratory conditions, which can pose significant challenges, such as the difficulties associated with extraction from the source tissue, ethical concerns about separating cells from human or animal models, limited cell passage ability, and variation in results due to differences in the source of the obtained cells, among other issues. In general, cells in laboratory conditions can divide into a limited number, known as the Hayflick limit, due to telomere erosion at the end of each cellular cycle. Given this problem, researchers require cell lines that do not enter the senescence phase after a limited number of divisions. This can allow for more stable studies over time, prevent the laborious work associated with cell separation and repeated cultivation, and save time and money in research projects. The aim of this review is to summarize the function and effect of immortalization techniques, various methods, their advantages and disadvantages, and ultimately the application of immortalization and cell line production in various research fields.
15 August 2022 in Jentashapir Journal of Cellular and Molecular Biology
Background: Colorectal cancer (CRC) is one of the most common gastrointestinal cancers worldwide. It is the second leading cause of death in women after breast cancer. Objectives: The present study aimed to determine the cytotoxic effects of zinc oxide (ZnO) nanoparticles on colon cancer (SW480) viability and nitric oxide (NO) level in vitro. Methods: In this experimental study, the values of 15.62, 31.25, 62.5, 125, 250, and 500 μg/mL of ZnO nanoparticles were considered to treat SW480 cells for 24 hours. The MTT method was used to determine cell viability. The amount of NO was also measured using the grease method. An analysis of variance (ANOVA) was used to analyze the data. Results: Treatment of SW480 cells with ZnO nanoparticles resulted in decreased viability in a dose-dependent pattern. NO concentration significantly increased in response to an effective dose of ZnO nanoparticles (108 µg/mL) compared to the control group (P < 0.001). Conclusions: ZnO nanoparticles have cytotoxic effects on colon cancer cells. The cytotoxic effect of ZnO nanoparticles on colon cancer cells is partly mediated by NO in cancer cells.
24 February 2025 in Exploration of Targeted Anti-tumor Therapy
Glioblastoma, an aggressive and lethal brain tumor, presents enormous clinical challenges, including molecular heterogeneity, high recurrence rates, resistance to conventional therapies, and limited therapeutic penetration across the blood-brain barrier. The glioblastoma microenvironment, characterized by a dynamic interplay of cellular and non-cellular components, is a key driver of tumor growth and therapeutic resistance. Neuroinflammatory cytokines, particularly interleukins and tumor necrosis factor-alpha, play pivotal roles in this microenvironment, contributing to tumor progression and immune evasion. This review highlights oncolytic virotherapy as a promising therapeutic avenue, focusing on its potential to modulate neuroinflammatory responses, induce localized immune reactions, and deliver immunomodulatory factors directly to the tumor site. While encouraging outcomes have been observed, challenges such as overcoming the blood-brain barrier, managing host antiviral immunity, and mitigating potential risks to normal neuronal cells remain critical barriers to clinical translation. By analyzing the intricate interactions of oncolytic viruses with the glioblastoma microenvironment and synthesizing findings from preclinical and clinical trials, this review provides actionable insights into developing personalized and effective therapeutic strategies for this aggressive tumor based on oncolytic virotherapy alone or when using it combined with conventional therapies, immunotherapy, natural killer-cell therapy, chimeric antigen receptor-T cell therapy, and dendritic cell therapy.
1 January 2025 in Journal of Clinical Pharmacy and Therapeutics
Oncolytic viruses (OVs) are naturally occurring or genetically engineered viruses that selectively target and destroy cancer cells. They act through multiple mechanisms, including direct tumor cell lysis, stimulation of immune‐mediated cytotoxicity, and modulation of the tumor microenvironment (TME). Recent studies have shown that, beyond their direct oncolytic activity, OVs also influence the immune landscape by modulating the expression of PD‐1/PD‐L1 axis. In many cases, OVs trigger the release of proinflammatory cytokines, leading to increased PD‐L1 levels on immune cells. This upregulation plays a key role in modulating the TME and shaping immune checkpoint signaling. While there is also evidence that OVs can directly reduce PD‐L1 expression on tumor cells, the most prominent effect appears to be the boost in PD‐L1 expression. This shift is thought to be crucial in influencing how the immune system responds to tumors. These changes could modulate PD‐L1‐mediated immune suppression and alter the exhaustion and anergy rate of the effector tumor‐specific T cells infiltrated into the TME. This review discusses how OVs influence PD‐1 and PD‐L1 expression, with a focus on innate and adaptive immune activation, interferon signaling pathways, and engineered OVs designed to express immunomodulatory cytokines and chemokines. We explore how these mechanisms can be leveraged to enhance antitumor immunity, particularly in combination with ICIs. Furthermore, we discuss the potential of OVs to remodel the TME, modulate PD‐L1 expression, and promote immune‐mediated tumor clearance. Overall, this review highlights the evolving role of OVs in cancer therapy and their potential to augment the effectiveness of current immunotherapeutic strategies.
Background: The landscape of aesthetic medicine has increasingly favored minimally invasive interventions, with the 1470 nm diode laser (Endolift) gaining prominence as a viable alternative to surgical lifting for soft‐tissue remodeling and lipolysis. Aims: This narrative review synthesizes current evidence on the mechanism, clinical versatility, and safety profile of Endolift. A primary objective is to evaluate the synergistic potential of combining this technology with complementary aesthetic modalities to optimize patient outcomes. Patients/Methods: A comprehensive search of PubMed/MEDLINE, Scopus, and Google Scholar was conducted. We analyzed key literature on the 1470 nm diode laser, selecting studies that document its efficacy as monotherapy and in combination with injectables or regenerative techniques. Results: The 1470 nm wavelength exhibits high affinity for water, facilitating selective lipolysis and stimulating deep collagen restructuring through controlled photothermal interaction. Clinical findings consistently report tangible improvements in skin laxity and contouring with limited recovery time. Notably, multimodal protocols—integrating dermal fillers, nanofat, or surface resurfacing—appear to enhance aesthetic outcomes by simultaneously addressing volume deficits and superficial texture alongside tissue tightening. Conclusions: Endolift represents a robust, minimally invasive tool for facial and body sculpting. While current data support its efficacy, particularly within multimodal treatment plans, the standardization of protocols through larger, randomized controlled trials remains a priority to confirm long‐term durability.
The combination of Endolift laser therapy and injectable platelet‐rich fibrin (i‐PRF) is an emerging strategy in aesthetic medicine, but the optimal scheduling of these modalities remains unexplored. This case report highlights a novel treatment schedule combining i‐PRF and Endolift laser therapy, resulting in noticeable short‐term facial rejuvenation in a 56‐year‐old female. A 56‐year‐old woman presented with concerns regarding facial skin laxity and aging. A unique treatment schedule was implemented: i‐PRF injections were administered 1 day before (Day −1), 1 week after (Day +7), and 1 month after (Day +30) a single Endolift laser session (Day 0). At the 4‐week follow‐up, the patient demonstrated marked improvement in skin tightness, texture, and overall facial appearance, as assessed by clinical examination, standardized photography, and high patient‐reported satisfaction. Only mild, transient adverse effects were observed, with no delayed complications. This novel schedule combining i‐PRF and the Endolift laser demonstrates promising synergistic effects, resulting in significant short‐term skin rejuvenation. While these initial findings suggest that the precise timing of i‐PRF enhances the regenerative impact of Endolift therapy, further large‐scale studies utilizing objective measurement scales and extended follow‐up periods (3–6 months) are warranted to validate long‐term durability and establish standardized protocols.